NCT06770543 - Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea) | Biotech Hunter

Enrollment

1,500

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 2, 2031

Study Completion Date

January 2, 2031

Conditions

Primary Hypercholesterolemia or Mixed Dyslipidemia

Interventions

OTHER

Inclisiran

There is no treatment allocation. Patients administered Leqvio by prescription that have started before inclusion of the patient into the study will be enrolled.